Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-14-009153
Filing Date
2014-02-14
Accepted
2014-02-14 10:51:28
Documents
11
Period of Report
2013-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q v367325_10q.htm 10-Q 608086
2 EXHIBIT 31.1 v367325_ex31-1.htm EX-31.1 9960
3 EXHIBIT 31.2 v367325_ex31-2.htm EX-31.2 9915
4 EXHIBIT 32.1 v367325_ex32-1.htm EX-32.1 5543
5 EXHIBIT 32.2 v367325_ex32-2.htm EX-32.2 5501
  Complete submission text file 0001144204-14-009153.txt   3030704

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT tglp-20131231.xml EX-101.INS 339817
7 XBRL TAXONOMY EXTENSION SCHEMA tglp-20131231.xsd EX-101.SCH 37081
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tglp-20131231_cal.xml EX-101.CAL 31965
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tglp-20131231_def.xml EX-101.DEF 159746
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE tglp-20131231_lab.xml EX-101.LAB 195603
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tglp-20131231_pre.xml EX-101.PRE 193910
Mailing Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038
Business Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038 212-797-9877
Tongli Pharmaceuticals (USA), Inc. (Filer) CIK: 0001052284 (see all company filings)

EIN.: 841090791 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-52954 | Film No.: 14612280
SIC: 2834 Pharmaceutical Preparations